Dupilumab significantly improved esophageal distensibility and diameter in eosinophilic esophagitis at 24 weeks, alongside ...

Dupilumab and upadacitinib were associated with greater improvements in AD severity when compared with methotrexate, cyclosporine, and phototherapy.

A recent longitudinal cohort study found that dupilumab provides sustained, 12-month disease control for severe atopic ...

The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents. The association between dupilumab and psoriasis was ...

The monoclonal antibody countered some esophageal restructuring caused by inflammatory dri ...

Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...

Improvements in lung function occurred as early as 2 weeks after the first dose of treatment. A pivotal phase 3 trial found that dupilumab (Dupixent) significantly reduced severe asthma attacks over 1 ...

Credit: Medical Images. A PDUFA target date of January 31, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is approved for atopic dermatitis in children aged 6 months and older. Patients on dupilumab did not ...

Dupilumab (Dupixent) relieves signs and symptoms of eosinophilic esophagitis (EoE) for up to 52 weeks, researchers say. Few side effects, other than injection pain, emerged in the year-long phase 3 ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 open ...